To define the possible role of serology in the diagnosis and prognosis of visceral leishmaniasis (VL) in patients with human immunodeficiency virus type-1 (HIV-1) infection, the dynamics of humoral immune responses was investigated in 20 coinfected patients. Sequential sera obtained before, during, and after VL diagnosis were analyzed by an indirect immunofluorescent antibody test (IFAT), a recombinant ELISA (using the rK39 protein), and immunoblotting. During the active course of the disease, positive results were found by IFAT or ELISA in 22% of the cases and by immunoblotting in 78% of the cases. A great variability in the response was observed during the follow-up with a trend to more positive results near the time of VL diagnosis. Forty-six percent of the patients were positive by IFAT or ELISA on at least one time point before VL and 37.5% were positive during the period following treatment. These results confirm the limited usefulness of the IFAT and ELISA in the diagnosis of VL in coinfected patients and demonstrate their low ability to predict the development or the outcome of disease. In these patients, immunoblotting could be a useful tool for studying the natural course of leishmaniasis, although it has limited value for diagnosis or treatment control.
Leishmaniases are present in 88 countries where they affect some 14 million people. 1 Visceral leishmaniasis (VL) is a severe form of the disease usually observed in nonimmunocompromised hosts in endemic areas. It has also been seen as a complicating infection in immunosuppressive conditions, such as hematologic malignancies, autoimmune diseases, or corticosteroid therapy. [2] [3] [4] Since human immunodeficiency virus type-1 (HIV-1) is a frequent cause of immunosuppression, it is not surprising that an increasing number of cases of leishmaniasis have been described in HIV-1-infected individuals in areas where both infections overlap. In the Mediterranean area, since the HIV epidemic started, there has been a dramatic increase of VL in adults, mainly in HIV-1 coinfected patients, with several-fold increases recorded in the rate of VL associated with HIV-1. In fact, it is estimated, that in southern Europe, between 1.5% and 9% of all patients with acquired immunodeficiency syndrome (AIDS) will develop VL 5, 6 and more than 700 cases of coinfection have been reported up to now in this area, with the majority from Spain. 6 The overlapping of both infections in the Mediterranean basin represents a severe health problem and has become a major concern of the World Health Organization. 6, 7 Unfortunately, diagnosis of leishmaniasis is difficult in patients with HIV-1 infection. Clinical diagnosis is limited since other HIV-associated opportunistic infections that resemble signs and symptoms of leishmaniasis appear at the time of VL diagnosis in more than 65% of the cases. 8 From a practical point of view, a definitive diagnosis of VL is established by direct observation of the parasite in tissue samples (bone marrow, spleen, lymph node, liver) and/or its isolation in culture. However, biopsy techniques are invasive, and can be complicated by the general deterioration of these patients in the advanced stages. Moreover, culture procedures are relatively insensitive and time-consuming. 9 The demonstration of the parasite in peripheral blood smears has been recently proved to be a quick, easy, and noninvasive diagnostic method in patients coinfected with HIV-1, 10-12 but a low sensitivity limits the yield of this technique. 12 The amplification of specific sequences of Leishmania DNA by polymerase chain reaction (PCR) techniques is another approach recently developed, [13] [14] [15] but problems in standardization have been found. Serologic tools are simple and noninvasive approaches shown to be useful in the diagnosis of VL in immunocompetent individuals. 16 Because impaired cell-mediated immunity is a main characteristic of HIV-1 infection, specific humoral immune response to Leishmania in coinfections seems to be partial, weak, or absent. 8 However, little is known about the serologic pattern of response to Leishmania in coinfected individuals and the few results reported are often incomplete and discrepant. 8, [17] [18] [19] [20] [21] The aim of the present study was to describe the dynamics of antibodies responses to Leishmania in patients coinfected with HIV-1 in order to define the possible role of serology in the diagnosis and prognosis of VL in these patients.
PATIENTS AND METHODS
Population studied. From January 1990 to December 1994, 72 patients was diagnosed with VL and HIV-1 infection at the Virgen del Rocio University Hospital, Seville, Spain. Patient information, including demographic variables, HIV infection stage, opportunistic infections, other AIDSrelated events, conventional laboratory and immunologic data, antimicrobial therapy and outcome, was recorded using a standardized form. Diagnosis of VL and relapses were verified in each case by the demonstration of Leishmania amastigotes in tissue or by isolation of the parasite in Novy-Nicolle-McNeal's (NNN) medium. Infection with HIV-1 and stage and diagnosis of AIDS were defined according to Centers for Disease Control and Prevention (CDC) (Atlanta, GA) criteria. 22 The patients were treated with one of the following therapeutic regiments: 1) meglumine antimoniate, 20 mg/kg of pentavalent antimonials/day (alone or with oral allopurinol at 900 mg per day) for up to 21 days; 2) pentamidine isothianate, 4 mg/kg/day, for up to 15 days; 3) amphotericin B at a total dose of 1.000-1.500 mg. Microbiologic cure was defined as absence of Leishmania amastigotes in bone marrow aspirates after a full course of treatment.
Initial clinical response was defined as remission of fever and improvement of hematologic values after treatment. Our study population was composed of the 20 of 72 cases of VL in HIV-1-infected patients from which sequential serum samples were available. A total of 212 serum specimens was analyzed in the study. In 18 of 20 cases a sample obtained at the time of parasitologic diagnosis of VL and before starting specific treatment was available. In 13 of 20 subjects serum specimens obtained before the onset of clinical VL were also available (pre-VL samples). The mean Ϯ SD pre-VL period was 40.08 Ϯ 24.86 months (range ϭ 1-84 months). In addition, 16 patients were followed serologically after the VL diagnosis (post-VL samples) for a mean Ϯ SD period of 15 Ϯ 9.65 months (range ϭ 2-31 months). In all cases sequential clinical and immunologic information was available. Serum samples were stored at -20ЊC until examination.
Informed consent was obtained from the patients for participation in all studies. This protocol was designed and performed according to the Helsinki Declaration and was approved by the Research Ethics Committee, Hospital Virgen del Rocio, Seville, Spain.
The general characteristics of the population studied, including relevant epidemiologic and clinical data, antimicrobial therapy, and outcome during the follow-up, are summarized in Table 1 . The group of 72 patients who were diagnosed with VL and HIV-1 coinfection at our hospital and the study population considered herein were comparable in terms of sex distribution (male 84% versus 90%; P ϭ 0.43), age (32. Controls. A total of 74 serum specimens were used as controls. These sera were divided into four groups.
Group 1 (HIV-/VL-from a nonendemic area). Serum specimens were obtained in 1994 from 20 healthy, voluntary blood donors from a leishmaniasis nonendemic area of northern Spain (Asturias). None of them had a history of leishmaniasis or belonged to any risk group for parenterally transmitted viruses.
Group 2 (HIV-/VL-from an endemic area).
Serum specimens were obtained in 1992 from 20 healthy adults from our environment (Seville), which known to be endemic for VL. None of them had a history of parasitic infections or belonged to any risk group for parenterally transmitted viruses.
Group 3 (HIVϩ/VL-). Serum samples were obtained from 14 HIV-1-infected patients who died in our hospital between 1990 and 1994 of a non-VL cause. None of them had a history of leishmaniasis. In all cases a complete macroscopic and microscopic post-mortem examination was performed, which revealed absence of Leishmania infection.
Group 4 (HIV-/VLϩ). Serum samples were obtained from 20 nonimmunocompromised patients in Spain diagnosed as having VL between 1990 and 1994.
Parasites and antigen preparation. Leishmania infantum MON-1 (MHOM/FR/78/LEM-75) promastigotes were grown at 28ЊC in RPMI 1640 medium (Gibco, Paisley, Scotland) supplemented with 100 IU/ml of penicillin, 100 g/ml of streptomycin, 2 mM L-glutamine, and 10% heat-inactivated fetal calf serum (Boehringer Mannheim, Meylan, France). After reaching the stationary phase, the parasites were har- (100) 2 (11) 0 (0) 0 (0) 3 (21) 19 (95) 4 (22) NC 0 (0) 2 (14) 20 (100) 14 (78) * HIV-1 ϭ human immunodeficiency virus type-1; VL ϭ visceral leishmaniasis; NC ϭ negative control sera.
† Indirect immunofluorescent antibody test (IFAT) titers Ͼ 1:80 were considered to be positive.
‡ Cut-off optical density ϭ 0.062. § Immunoblot reactive: evidence of one or more bands of any molecular weights detected in at least two patients with VL but not in the negative control sera from a nonendemic area.
¶ Blood donors from a nonendemic area for VL (Asturias). # Healthy adults from an endemic area for VL (Seville).
vested, washed in phosphate-buffered saline (PBS), and used to prepare soluble leishmanial antigen as previously described. 23 Protein concentrations were determined using the bicinchoninic acid protein assay (Pierce, Rockford, IL). The rK39 antigen is a recombinant protein that contains a 39-amino acid repeat. This antigen is a 298-amino acid sequence with a predicted molecular mass of 32.7 kD and an isoelectric point of 4.4. This product is part of a 230 kD protein predominant in L. chagasi tissue amastigotes. 24 The antigen was kindly provided by Steven G. Reed (Seattle Biomedical Research Institute, Seattle, WA).
Indirect immunofluorescent antibody test (IFAT). Stationary phase promastigotes were washed three times in PBS, and 10 l of a 2 ϫ 10 7 parasites/ml suspension were dispensed in 15-well immunofluorescence slides. Slides were air-dried for 1 hr at 37ЊC and fixed with cold acetone (-20ЊC) for 5 min. Patient and control sera were assayed in serial two fold dilutions from 1:10 to 1:640 and incubated with parasites for 30 min at 37ЊC. After three washes in PBS, antibody fixation was revealed with fluorescein isothiocyanate-conjugated sheep anti-human IgG (heavy plus light chains) (ICN, Aurora, OH) diluted at 1:150 in 0.01% Evans blue for counterstaining. The slides were then incubated for 30 min at 37ЊC, washed, and examined under with a fluorescence microscope (Carl Zeiss, Oberkochen, Germany). The IFAT results were regarded as positive when a 1:80 dilution of the serum gave fluorescence. This cut-off value was established as a result of combining the highest sensitivity and specificity for a group of sera from VL patients and healthy subjects from endemic areas in which the correlation with parasitologic findings was assessed.
The rK39 antigen ELISA (ELISA-rK39). Patient and control sera described above were tested by ELISA for antibody levels to rK39 antigen as previously described. 24 The working strengths of the antigen and the serum were determined by checkerboard titration. The ideal antigen/serum combination giving the best differentiation between negative and positive sera was chosen (50 ng/well; 1:100 serum dilution). Each serum was assayed in duplicate. The optical density of the well was read at 405 nm. The cut-off value to determine positivity was defined as the mean optical density of negative controls from our area (HIV-/VL-, group 2) plus three times the standard deviation (optical density ϭ 0.062).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting. Soluble L. infantum antigen was electrophoretically separated by SDS-PAGE according to the method of Laemmli 25 with a 4% stacking gel and 12.5% resolving gel under denaturing conditions. Fifty micrograms of proteins/cm of gel was electrophoresed for 2-3 hr at 30 mA/gel. The separated proteins were transferred onto a 45-m pore size nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) in 25 mM Tris, 192 mM glycine, 0.1% (w/v) SDS, 20% (v/v) methanol buffer, pH 8.3, at 0.8 mA/cm 2 for 1 hr. After blocking in Tris buffer solution (TBS, 50 mM Tris-HCl, 150 mM NaCl, pH 7.4) with 3% (w/v) bovine serum albumin (Sigma, St. Louis, MO) at 4ЊC overnight, the nitrocellulose was cut into 6-mm strips. The strips were incubated for 2 hr at room temperature with the respective sera in a 1:100 dilution in blocking solution. After three washes (5 min each) in TBS containing 0.05% (v/v) Tween-20 (TBS-T), the strips were then incubated for 2 hr at room temperature with alkaline phosphatase-conjugated goat anti-human IgG (heavy plus light chains) (Bio-Rad, Richmond, CA) diluted 1:3,000 in TBS with 1% (w/v) bovine serum albumin and washed again twice in TBS-T and once in TBS. Enzymatic activity was revealed using 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (Bio Rad) at concentrations of 0.15 mg/ml and 0.3 mg/ml, respectively, in carbonate buffer (100 mM NaHCO 3 , 1.0 mM MgCl 2 , pH 9.8).
Immunoblots were performed with serum samples from all controls and with the 18 sera from patients coinfected with acute clinical VL. In addition, samples positive by ELI-SA-rK39 or IFAT during the pre-or post-VL follow-up were analyzed by immunoblot. Due to the lack of a homogeneous criterium of positivity by Western blot in the literature, we considered an immunoblot reactive when one or more bands of any molecular weight detected were present in at least two patients with VL, but not in the negative control sera from the nonendemic area (group 1). Immunoblots were considered negative when no bands were present or the criterion for a reactive immunoblot was not satisfied.
All serologic assays were conducted in a blinded fashion without knowledge of the subject's HIV-1 or VL status.
Statistical analysis. Results are expressed as mean Ϯ 1 SD values unless otherwise stated. The Mann-Whitney Utest and the Student's t-test were used to assess differences in the study variables between patients with positive and negative anti-Leishmania serologic results. The Fisher's exact test was used to assess the association of categorical variables to positive anti-Leishmania serologic status. Results were considered to be statistically significant at P Ͻ 0.05. All analyses were done using SPSS (Statistical Package for Social Studies, SPSS Inc., Chicago, IL) software.
RESULTS

Controls.
Serum samples from negative controls (groups 1 and 2) were negative by the IFAT, the ELISA-rK39, and immunoblot analysis (Table 2 and Figure 1 ). In five sera from group 1 (healthy donors from the nonendemic area), weak recognition of 32-kD, 46-kD, and 113-kD (two sub- jects) or 29-kD plus 65-kD bands was observed by immunoblotting ( Figure 1 ). These reactivities were considered nonspecific. Serum samples from group 2 (healthy controls from the endemic area) were negative by immunoblot. Three (21.4%) of 14 specimens from the HIV-1-positive patients without evidence of Leishmania infection (group 3) were positive by ELISA-rK39 and none were positive by IFAT (Table 2) . Two (14.3%) sera from this group were reactive by immunoblot, showing the presence of a weak band of 42 kD in one case and 76 kD in the other (Figure 1 ). Finally, all the nonimmunocompromised VL patients (group 4) were positive by IFAT and 19 of 20 were positive by ELISA-rK39 ( Table 2 ). The blot analysis showed multiple diagnostic bands in all cases tested except for one case with an isolated recognition of a 62-64-kD band (Figure 1) .
Antibodies response during acute VL in HIV-1-infected patients. Significant titers of antileishmanial antibodies were detected by IFAT in only two (11%) of 18 patients analyzed. The ELISA-rK39 result was positive in four (22%) cases (two of them also positive by IFAT); 14 (78%) of 18 sera were reactive by immunoblot. In 11 (61%) of 18 sera, we noted the recognition of at least two antigens of L. infantum. One isolated band was observed in three cases and no reactivities were detected for the other four subjects (Tables 2 and 3).
Immunoblot analysis revealed numerous antigens, which had a molecular weight range of 9-134 kD. The banding patterns of patients sera were complex and heterogeneous, and included bands in regions at 9-18, 22-28, 30-39, 40-48, 54-57, 62-67, 70-76, 94-98, and 127-134 kD ( Figure  1 and Table 3 ). Most of the serologic reactivity could not be attributed to nonspecific binding to parasite antigens, as was evident for negative reactivity in negative control sera.
No correlation was observed between positive results by IFAT or ELISA-rK39 and baseline CD4ϩ cell count (77 Ϯ 20.4/mm 3 versus 91.5 Ϯ 85.7/mm 3 ; P ϭ 0.59) or AIDS diagnosis at clinical VL (2 of 4 versus 5 of 14; P ϭ 0.34). No relationships were found between positive results of serology by IFAT, ELISA-rK39, or immunoblot and the route of acquisition of HIV infection or the mortality during the first episode of VL.
Serologic pattern before the first episode of VL. A diagram for individual serologic results by IFAT/ELISA is shown in Figure 2 . Six (46%) of 13 patients evaluated were positive by IFAT or ELISA in at least one time point before the onset of clinical leishmaniasis (pre-VL seropositive subjects). Overall, we observed a great variability in serologic response with a trend to more positive results near the time of VL diagnosis. In the pre-VL seropositive subjects, the pattern of response was often fluctuating and predominantly negative results were observed. Two of these patients gave positive results six and three years before the diagnosis of VL was made (patients 1 and 17; Figure 2 ). Three of six pre-VL seropositive subjects had acquired HIV-infection by the nonintravenous route (patients 1, 18, and 20; Figure 2) .
Serologic profile during the post-treatment follow-up. A scheme for the individual serologic course during the post-VL follow-up is shown in Figure 2 . Six (37.5%) of 16 patients were found to be positive by IFAT or ELISA-rK39 in at least one point during the period following treatment (post-VL seropositive subjects). Again, the response observed were variable and fluctuating. A persistent positive serologic response was found in the two patients who presented a relapsing VL course (patients 2 and 4; Figure 2 ). However, this pattern of response was observed in apparently cured individuals (patient 8). No correlation was observed between serologic response during the post-treatment follow-up and initial CDC stage, baseline CD4ϩ cell count, microbiologic cure, initial clinical response, course of VL or global mortality. Results of immunoblotting in the patients with antiLeishmania reactivities. Twenty-seven of the sequential serum samples evaluated were positive by IFAT and/or ELI-SA-rK39. In 13 (48%) of the 27 sera the immunoblot was reactive according to the criteria considered. An isolated nonspecific 28-kD band was observed in two cases and no reactivities were detected for the other 12 sera. Again a high intra-and inter-individual variability was observed in the pattern of response (Figure 1 and Table 3 ).
DISCUSSION
Our results confirm the low sensitivity of the conventional serologic tests (IFAT and ELISA) in the diagnosis of VL in patients coinfected with HIV-1 and demonstrate for the first time their limited value to predict the onset of clinical disease or the future evolution of the Leishmania coinfection.
The population considered in our study was composed of a homogeneous group of patients who were diagnosed with VL and HIV-1 infection at one tertiary center in the last four years and who were regularly assessed clinically and immunologically. No difference was apparent in regard to sex, age, basal CD4ϩ cell count, or initial clinical stage between our study population and all the VL and HIV-1 coinfected patients followed in our institution during the same period. Laboratory investigators were unaware of HIV or VL status, so this did not bias the interpretation of diagnostic procedures. The small number of cases included and the retrospective design are two circumstances that could have somewhat limited our results. These limitations have been observed in all previous studies. 8, [17] [18] [19] [20] [21] However, the homogeneity of our study population, the availability of sequential biological specimens before, during, and after VL diagnosis and the well-selected controls provided an appropriate situation to appraise the pattern of antileishmanial serologic response in patients coinfected with HIV-1.
Most previous clinical series of cases of Leishmania-HIV-1 coinfection report a low sensitivity for commercial IFAT or ELISA serologic tests, which are positive in only 5-50% of the patients. 6 Significant titers of antileishmanial antibodies have been recently reported in 82-95% of these patients using an in-house IFAT that uses promastigotes of a strain of L. infantum zymodeme MON-1 as antigen. 20, 21 In our series of 18 patients, 16 showed negative results using a similar IFAT. The conservation of the K39 epitope among visceralizing species of Leishmania from different geographic regions accounts for the serodiagnostic potential of rK39 product that was shown previously with subjects from Brazil, Africa, and Asia, 24, 26 but not in patients from Europe. However, in our experience the use of ELISA-rK39 increases the sensitivity of IFAT slightly (22%). Thus, our IFAT or ELISA-rK39, although being more than 95% sensitive in immunocompetent VL patients, yielded a low sensitivity in coinfected individuals, at least in our environment and with the conventional diagnostic criteria considered in our study.
The low antileishmanial antibody responses observed in coinfected patients can be expected since HIV-1 infection is associated with pronounced disregulation of the immune system, with a continued polyclonal activation of B lymphocytes and impairment of antigen presentation. It has been estimated that specific antiparasite antibody levels in AIDS patients are approximately 50-fold lower than in patients with normal immunity. 19 This could explain the high percentage of coinfected patients showing a partial, weak, or absent antibody response to Leishmania, as for other infections. 27, 28 During the past few years, numerous studies have investigated Leishmania antigen expressions at the level of specific antibody recognition. Using immunoblotting techniques, several L. infantum antigens that appeared promising for establishing an immunodiagnosis of VL in nonimmunocompromised hosts have been identified: 70-72 kD, 29 94 kD, 30 14-16 kD, 19 39 kD, 24 and 32 kD, 31 but a clear pattern of specific immune response to parasite antigens during the active course of the disease has not been yet defined. These approaches using blot analysis are of special interest for HIV-1-infected patients in which the serologic response based on IFATs or ELISAs is frequently negative. Only three previous studies 19, 21, 32 have evaluated by immunoblot the antibody response to L. infantum in patients coinfected with HIV. Mary and others 19 in a series of 11 AIDS cases found a similar pattern of reactivity between HIV and non-HIV patients with VL that differed only in the variable presence of a 14-kD band in the former group. The 16-kD antigenic component was considered as the more sensitive and specific diagnostic band. Gari-Toussaint and others 21 in another study carried out in the same endemic area (southern France) reported the presence of bands of molecular mass 14 kD and 16 kD in 13 of the 18 evaluated cases. Cardeñosa and others 32 found that a 17-kD band had a predictive value of cure after chemotherapy in the three patients evaluated.
In our study, immunoblots were found to be reactive during the active course of the disease in 78% of the cases. These results confirm that immunoblotting provides a significant increase in the sensitivity for which specific antibodies to Leishmania could be detected. Unlike the previously reported experience, 19, 21, 32 the pattern of reactivity observed during the acute VL disease was very variable in our HIV-infected patients and clearly weaker than in the nonimmunocompromised VL patients. However, strict comparisons between our results and other results reported in the literature are rather difficult because of the variability in the techniques and the use of different strains and antigens.
Although no obvious immunodominant antigen was found in this analysis, five groups or parasite antigens (14 kD, 42-43 kD, 57 kD, 76 kD, and 94 kD) appear to have potential use for diagnosis purposes in HIV-infected individuals. Since not every patient will always immunologically respond to the same antigen(s), and considering the high variability of the immunoblot patterns, it seems that a combination of several antigens should be used, as has been previously suggested. 30 Further studies are required to more precisely define the immunoblot diagnostic criteria for VL.
From an epidemiologic point of view, an important question is whether the higher prevalence of Leishmania infection in HIV patients is due to a greater number of people infected or if it is due to transmission through the sharing of a hypodermic needles by coinfected patients, the main route of HIV transmission in areas in which both infections overlap. 33 Our study is the first to examine the antibody response to Leishmania before the onset of clinical VL in coinfected patients. Interestingly, three patients showing a pre-VL seropositive response acquired HIV infection by a nonintravenous route. Furthermore, evidence of exposure to Leishmania antigens at least two years before the development of the acute disease was found in four of these pre-VL seropositive individuals. Taken together, these findings favors the hypothesis of asymptomatic infection reactivation, although both possibilities cannot be excluded.
Finally, we have studied the possible role of serology as a marker of VL outcome in coinfected patients. The aim was to look for noninvasive diagnostic methods to guide more intensive therapeutic strategies for chronic-relapsing patients. In nonimmunocompromised hosts, two preliminary studies 19, 32 have shown that antibodies to Leishmania remain in the sera of cured patients for years, but a progressive decrease in responses with time was observed. The relatively low number of patients studied did not allow final conclusions to be made. We have found a persistent positive serologic response by IFAT or ELISA-rK39 in two patients who relapsed after the first VL episode, but a similar serologic pattern was observed in five apparently cured individuals. Therefore, in addition to the low sensitivity observed for these serologic tools, their value to predict the clinical course of VL in these individuals was limited. Immunoblot analysis revealed a progressive disappearance of band recognition in all the apparently cured individuals and a more persistent antibody response in those who relapsed. Analysis of this possible transitory pattern requires further study.
In conclusion, the data presented herein confirm the limited usefulness of the IFAT and ELISA-rK39 in the diagnosis of VL in patients coinfected with HIV-1, and demonstrate for the first time their low ability to predict the development or the outcome of leishmaniasis in HIV-1 patients. Immunoblotting may offer a more sensitive and specific approach to the diagnosis of VL, which provides useful information to study the natural course of HIV-1-Leishmania coinfection. However, the high variability in the antibody response observed in coinfected patients indicates that it will be difficult in this situation to use Western blotting analysis for clinical diagnosis or treatment control.
